GlassScriptPhysician profile
Hans J Fuchs
NPI 1124051669
$22,842.36
in general payments reported to CMS, 2019-2025
55 companies · $3,120 in 2025
The $3,120 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,920 · 2020: $2,335 · 2021: $2,753 · 2022: $5,603 · 2023: $3,055 · 2024: $3,058 · 2025: $3,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,189 · Education: $43.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,188.55 |
| Education | $43.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,071.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Activ Surgical, INC. | $2,750.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $2,258.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,020.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,973.94 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,652.76 | 2019-2025 | |
| Amgen INC. | $1,453.43 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $1,418.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,099.93 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $506.58 | 2019-2024 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $423.28 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Amarin Pharma, INC. | $325.67 | 2019-2022 | |
| Astellas Pharma US INC | $312.40 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $303.57 | 2020-2025 | Zoryve, Livalo |
| E.R. Squibb & Sons, L.L.C. | $301.07 | 2019-2025 | Eliquis, Camzyos |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Fuchs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.